Pharmaceuticals
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the National Center for Drug Evaluatio...
2023-08-25 20:00
3173
Tigermed Reports 2023 Interim Results
HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
2023-08-25 18:39
5889
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics
YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine. Under the MOU, bo...
2023-08-25 15:14
2511
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the New Drug Application (NDA) for its...
2023-08-24 20:00
2559
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...
2023-08-24 14:00
4132
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
TOKYO, Aug. 23, 2023 /PRNewswire/ -- PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-de...
2023-08-24 09:51
2839
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...
2023-08-24 07:59
2503
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill
SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm
Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome
Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive
technology for scalp rejuvenation and hair growth.
2023-08-23 17:00
2592
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor
SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman's expertise in scientific research and clinical development, especially in the areas of oncolytic virus and immunotherapy, will greatly enhance ImmVira's re...
2023-08-23 10:51
2570
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH) – a global innovative pharmaceutical company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases – today release...
2023-08-22 20:58
3052
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug pro...
2023-08-22 20:00
2346
CARsgen Announced 2023 Interim Results
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights * Collaboration agr...
2023-08-22 19:30
4227
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...
2023-08-22 17:13
3042
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...
2023-08-22 08:59
2438
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer
The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this designation. PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immun...
2023-08-21 20:00
2621
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination fromAugust 19, 2023 to September 19, 2023, for each public share that...
2023-08-19 04:30
5877
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will e...
2023-08-18 20:00
7025
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life * IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering * IMG-007 is being evaluated in two global proof-of-concept trials SAN DIEGO,...
2023-08-18 19:00
5460
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17
CHANGZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), the world's leading provider of rehabilitation equipment, rang the bell at the New York Stock Exchange by its Chairman and CEOWang Erqi on August 17, to celebrate the Com...
2023-08-18 11:36
5038
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.
* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing and...
2023-08-18 08:58
3030
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 287 media titles]
2026-09-15 11:00
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 259 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
11761
